Navigation Links
PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:8/6/2008

development pipeline. Our priorities for Fiscal Year 2009 include solid revenue growth, as well as improved operating profitability and increased earnings per share. We expect to achieve these objectives while also making investments in our businesses in an effort to continuously improve the products and services that we offer to our clients, positioning us for sustained growth."

The Company issued forward-looking guidance for the first quarter of Fiscal Year 2009 (ending September 30, 2008), and updated guidance for Fiscal Year 2009, using recent exchange rates. Without taking into account the impact from the anticipated acquisition of ClinPhone (as announced on June 13, 2008), the Company expects to report consolidated service revenue for the first quarter in the range of $260 to $270 million, and earnings per diluted share in the range of $0.23 to $0.25. For Fiscal Year 2009, consolidated service revenue is expected to be in the range of $1.125 to $1.155 billion and earnings per diluted share are projected to be in the range of $1.15 to $1.25 (versus previously issued revenue guidance for Fiscal Year 2009 of $1.110 to $1.140 billion, and earnings per diluted share of $1.10 to $1.20).

The Company currently anticipates that the acquisition of ClinPhone will be completed in the course of the first quarter of Fiscal Year 2009. When taking into account the impact from the anticipated acquisition, the Company expects that there will be a dilutive impact to earnings per share in Fiscal Year 2009 in the range of $0.04 to $0.06, including the amortization of intangibles and other costs. Upon closing of the transaction, PAREXEL will also be taking a one-time charge to write off costs associated with unamortized loan fees in connection with its existing line of credit and costs related to unwinding of interest rate hedges. The Company anticipates these costs will have a dilutive impact to earnings per share in Fiscal Year 2009 of approximately $0.02. Due to U
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
4. PAREXEL Expands Global Clinical Logistics Capabilities
5. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
6. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
7. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
8. PAREXEL Reaches Agreement To Acquire ClinPhone
9. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
10. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
11. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Ondine Biopharma,Corporation (TSX: OBP; AIM: OBP), a ... that a poster entitled,"Photodisinfection in the Treatment ... representatives at the American Academy of,Periodontology,s (AAP) ... being,held at the Washington State Convention and ...
... XI,AN, China, Sept. 5 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical ... leading developer and producer of plant extracts and ... food production in,Xi,an, China, is pleased to announce ... arrangement with Xi,an Qinba Xintong Medical Ltd. ("Qinba").,Under ...
... MEDQ ) today announced that its board of directors has ... join the board, effective,September 4, 2008. Prior to the election ... of the board from seven to 10 members., According ... to have this opportunity to further enhance the quality and,experience ...
Cached Biology Technology:Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontology's 94th Annual Meeting 2Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd. 2MedQuist Announces Additions to Board of Directors 2MedQuist Announces Additions to Board of Directors 3
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... very good at what they do. But they don,t ... work in oily or dangerous environments, or in any kind ... of the fastest and most maneuverable creatures on the planet, ... to their streamlined bodies and a finely tuned muscular/sensory/control system. ...
... Rochelle, NY, September 19, 2012 Many biotech observers ... be based on the field of personalized medicine, ... ( GEN ) ( http://genengnews.com ). Although drug ... of biosamples, demand is exceeding supply, fueling the ...
... researchers at Michigan State University has documented the step-by-step process ... in the current issue of Nature , are revealed ... coli bacteria figured out how to supplement a traditional ... "It,s pretty nifty to see a new biological function evolve," ...
Cached Biology News:Robotic tuna is built by Homeland Security 2Evolution is as complicated as 1-2-3 2